1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2016

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2016’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
- The report reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics and enlists all their major and minor projects
- The report assesses Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
Introduction 7
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Overview 8
Therapeutics Development 9
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics under Development by Companies 11
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 18
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Products Glance 20
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Products under Development by Companies 24
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Products under Investigation by Universities/Institutes 33
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development 36
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment 119
Drug Profiles 131
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Recent Pipeline Updates 337
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects 394
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products 402
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones 403
Appendix 409

List of Tables
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2016 27
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis, H1 2016 28
Number of Products under Development by Companies, H1 2016 29
Number of Products under Development by Companies, H1 2016 (Contd..1) 30
Number of Products under Development by Companies, H1 2016 (Contd..2) 31
Number of Products under Development by Companies, H1 2016 (Contd..3) 32
Number of Products under Development by Companies, H1 2016 (Contd..4) 33
Number of Products under Development by Companies, H1 2016 (Contd..5) 34
Number of Products under Development by Companies, H1 2016 (Contd..6) 35
Number of Products under Investigation by Universities/Institutes, H1 2016 36
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 37
Comparative Analysis by Late Stage Development, H1 2016 38
Comparative Analysis by Clinical Stage Development, H1 2016 39
Comparative Analysis by Early Stage Development, H1 2016 40
Comparative Analysis by Unknown Stage Development, H1 2016 41
Products under Development by Companies, H1 2016 42
Products under Development by Companies, H1 2016 (Contd..1) 43
Products under Development by Companies, H1 2016 (Contd..2) 44
Products under Development by Companies, H1 2016 (Contd..3) 45
Products under Development by Companies, H1 2016 (Contd..4) 46
Products under Development by Companies, H1 2016 (Contd..5) 47
Products under Development by Companies, H1 2016 (Contd..6) 48
Products under Development by Companies, H1 2016 (Contd..7) 49
Products under Development by Companies, H1 2016 (Contd..8) 50
Products under Investigation by Universities/Institutes, H1 2016 51
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 52
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 53
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Limited, H1 2016 54
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Actelion Ltd, H1 2016 55
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H1 2016 56
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AIMM Therapeutics B.V., H1 2016 57
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alchemia Limited, H1 2016 58
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Plc, H1 2016 59
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AlphaMab Co., Ltd, H1 2016 60
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alvogen Korea Co., Ltd., H1 2016 61
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corporation, H1 2016 62
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AnGes MG, Inc., H1 2016 63
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corporation, H1 2016 64
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Arsanis Biosciences GmbH, H1 2016 65
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AstraZeneca Plc, H1 2016 66
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 67
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bavarian Nordic A/S, H1 2016 68
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech International Limited, H1 2016 69
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by BioDiem Ltd, H1 2016 70
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by C3 Jian, Inc, H1 2016 71
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cellceutix Corporation, H1 2016 72
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cempra, Inc., H1 2016 73
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ContraFect Corporation, H1 2016 74
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics, Inc., H1 2016 75
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CSA Biotechnologies LLC , H1 2016 76
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA , H1 2016 77
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DesignMedix, Inc., H1 2016 78
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Limited, H1 2016 79
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 80
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ensol Biosciences Inc., H1 2016 81
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Excelimmune, Inc., H1 2016 82
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Galapagos NV, H1 2016 83
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Inc., H1 2016 84
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Gero Corp, H1 2016 85
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix, Inc., H1 2016 86
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics, LLC, H1 2016 87
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2016 88
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Immupharma Plc, H1 2016 89
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc., H1 2016 90
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics, Inc., H1 2016 91
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 92
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lascco SA, H1 2016 93
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences, Inc, H1 2016 94
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics B.V., H1 2016 95
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics, Inc, H1 2016 96
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck and Co., Inc., H1 2016 97
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix, Inc., H1 2016 98
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016 99
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MorphoSys AG, H1 2016 100
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Motif Bio Plc, H1 2016 101
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics AG, H1 2016 102
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NanoBio Corporation, H1 2016 103
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nemus Bioscience, Inc., H1 2016 104
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2016 105
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novabiotics Limited, H1 2016 106
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovaDigm Therapeutics, Inc., H1 2016 107
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2016 108
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Omnia Molecular Ltd., H1 2016 109
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oragenics, Inc., H1 2016 110
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Pepscan Presto BV, H1 2016 111
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Pfizer Inc., H1 2016 112
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Phico Therapeutics Limited, H1 2016 113
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Procarta Biosystems Limited, H1 2016 114
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Recce Limited, H1 2016 115
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Redx Pharma Plc, H1 2016 116
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2016 117
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Savara Inc., H1 2016 118
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 119
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H1 2016 120
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Soligenix, Inc., H1 2016 121
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics, Inc., H1 2016 122
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Taejoon Pharm Co., Ltd., H1 2016 123
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H1 2016 124
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Telephus Medical LLC, H1 2016 125
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 126
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TGV-Laboratories, H1 2016 127
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Theravance Biopharma, Inc., H1 2016 128
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Trellis Bioscience, Inc., H1 2016 129
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by United Therapeutics Corporation, H1 2016 130
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Valevia UK Limited, H1 2016 131
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by VLP Biotech, Inc., H1 2016 132
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wintermute Biomedical LLC, H1 2016 133
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wockhardt Limited, H1 2016 134
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by XBiotech USA, Inc., H1 2016 135
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 136
Assessment by Monotherapy Products, H1 2016 137
Assessment by Combination Products, H1 2016 138
Number of Products by Stage and Target, H1 2016 140
Number of Products by Stage and Mechanism of Action, H1 2016 143
Number of Products by Stage and Route of Administration, H1 2016 146
Number of Products by Stage and Molecule Type, H1 2016 148
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics - Recent Pipeline Updates, H1 2016 355
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2016 412
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..1), H1 2016 413
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..2), H1 2016 414
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..3), H1 2016 415
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..4), H1 2016 416
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..5), H1 2016 417
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..6), H1 2016 418
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..7), H1 2016 419
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products, H1 2016 420

List of Figures
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2016 27
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis, H1 2016 28
Number of Products under Development by Companies, H1 2016 29
Number of Products under Investigation by Universities/Institutes, H1 2016 36
Comparative Analysis by Clinical Stage Development, H1 2016 39
Comparative Analysis by Early Stage Products, H1 2016 40
Assessment by Monotherapy Products, H1 2016 137
Assessment by Combination Products, H1 2016 138
Number of Products by Top 10 Targets, H1 2016 139
Number of Products by Stage and Top 10 Targets, H1 2016 139
Number of Products by Top 10 Mechanism of Actions, H1 2016 142
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 142
Number of Products by Top 10 Routes of Administration, H1 2016 145
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 145
Number of Products by Top 10 Molecule Types, H1 2016 147
Number of Products by Stage and Top 10 Molecule Types, H1 2016 147

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Benzyl alcohol is an aromatic alcohol, which is metabolized into benzoic acid inthe human body. Benzyl alcohol is manufactured by hydrolysis of benzyl chloride in the presence of soda ash through the toluene ...

Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Silver sulfadiazine is an antibacterial drug used for making personal care products. Silver sulfadiazine is listed as the essential medicines by World Health Organization and is widely used as an antibiotic ...

Global Feed Antibiotics Market

October 2016 $ 4250

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.